MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Net income 2021–2025
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$227.3MFY2025 · since FY2021: -$4.5M → -$227.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$227.3M | -91.1% |
| FY2024 | -$118.9M | -230.3% |
| FY2023 | -$36.0M | +27.9% |
| FY2022 | -$50.0M | -1000.1% |
| FY2021 | -$4.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More MLTX financial trends
MLTX RevenueMLTX Net marginMLTX Gross profitMLTX Gross marginMLTX Operating incomeMLTX Operating marginMLTX Operating cash flowMLTX Free cash flowMLTX Capital expendituresMLTX Return on equityMLTX Stock buybacksMLTX Dividends paidMLTX Total assetsMLTX Total liabilitiesMLTX Shareholders’ equityMLTX overview →